Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 3/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
| ▸ | POLG | P54098 | 1/20 | 0.32 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13715042 | 0.91 | ABCB11 (0.32) | SLC22A6ABCB11POLA1POLGFAP | |
| SCHEMBL3853999 | 0.89 | SLC22A12 (0.31) | — | |
| SCHEMBL3852186 | 0.86 | SLC22A6 (0.46) | SLC22A6FGFR1CYP3A4ABCB11POLA1 | |
| SCHEMBL6004517 | 0.85 | FBP1 (0.30) | FBP1 | |
| SCHEMBL13715041 | 0.84 | FGFR1 (0.41) | SLC22A6FGFR1CYP3A4FBP1HPRT1 | |
| SCHEMBL3859402 | 0.84 | FGFR1 (0.41) | SLC22A6FGFR1CYP3A4FBP1HPRT1 | |
| SCHEMBL13714868 | 0.80 | — | — | |
| SCHEMBL13743277 | 0.80 | FGFR1 (0.42) | SLC22A6FGFR1CYP3A4FBP1HPRT1 | |
| SCHEMBL3857077 | 0.79 | FDPS (0.40) | SLC22A6FGFR1CYP3A4ABCB11POLA1 | |
| SCHEMBL13714861 | 0.77 | FAP (0.41) | SLC22A6FGFR1CYP3A4ABCB11POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1656387-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005012324-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | SLC22A6 1014/4885FGFR1 3686/4885CYP3A4 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.